Abivax
web2ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harn...
About
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
1 expert evaluated Abivax.
Experts evaluating Abivax
Explore the public profiles of experts who have evaluated this project.
Orbitrum Academy